La Jolla Pharmaceutical Co. (LJPC) - NASDAQ
  • Sep. 10, 2015, 9:11 AM
    | Sep. 10, 2015, 9:11 AM | 1 Comment
  • Sep. 8, 2015, 3:58 PM
    • Thinly traded La Jolla Pharmaceutical (LJPC +26.2%) is poised to finish the day up nicely on almost a 4x surge in volume. The market's positive action is certainly the biggest factor. Adding a bit of fuel to the up move was Chardan Capital's price target raise to $80 (83% upside) from $60.
    | Sep. 8, 2015, 3:58 PM | 11 Comments
  • Sep. 8, 2015, 12:41 PM
    | Sep. 8, 2015, 12:41 PM | 1 Comment
  • Aug. 21, 2015, 1:12 PM
    | Aug. 21, 2015, 1:12 PM | 8 Comments
  • Aug. 21, 2015, 12:45 PM
    | Aug. 21, 2015, 12:45 PM
  • May 11, 2015, 12:48 PM
    | May 11, 2015, 12:48 PM | 1 Comment
  • Apr. 21, 2015, 12:47 PM
    | Apr. 21, 2015, 12:47 PM
  • Jan. 7, 2015, 8:50 AM
    • Thinly-traded nano cap Galectin Therapeutics (NASDAQ:GALT) is up 49% premarket on robust volume in response to its report of results from a 30-patient Phase 1 study of GR-MD-02 in patients with nonalcoholic steatohepatitis (NASH).
    • The principal objective of the trial was to assess the safety, tolerability and pharmacokinetics of GR-MD-02 but investigators also noted a potential therapeutic effect on fibrosis as measured by a serum biomarker (FibroTest) and liver stiffness (FibroScan). Patients in cohort 3 who received 8 mg/kg GR-MD-02 showed a statistically significant reduction in FibroTest score versus placebo in one of the cohorts.
    • Fibrotest is a composite score of six blood tests that correlate to the extent of liver fibrosis.
    • NASH represents the next big potential payoff for drug firms after HCV.
    • Previously: Galectin NASH treatment meets primary endpoint in Phase 1 (Nov. 10, 2014)
    • NASH-associated tickers: (NASDAQ:GILD) (NASDAQ:SHPG) (NASDAQ:LJPC) (NASDAQ:CNAT) (NASDAQ:ICPT) (NASDAQ:RPTP)
    | Jan. 7, 2015, 8:50 AM | 1 Comment
  • Dec. 16, 2014, 12:58 PM
    • Thinly-traded nano cap La Jolla Pharmaceuticals (LJPC +9.8%) continues its up move on 3x surge in volume albeit on turnover of only 440K. Shares are now up over 40% since the close of $11.03 on December 10.
    • The company recently closed an exclusive worldwide license agreement with George Washington University covering intellectual property rights for the use of angiotensin II (LJPC-501) for the treatment of patients with hypotension and shock. The company plans to initiate a Phase 3 trial in Q1.
    | Dec. 16, 2014, 12:58 PM
  • Nov. 13, 2014, 4:10 PM
    • Thinly-traded nano cap LaJolla Pharmaceuticals (LJPC -15.9%) will finish in the red today on a 3x surge in volume as investors head for the exits after the company reported results from a 121-patient Phase 2 clinical trial evaluating the safety and efficacy of GCS-100 in patients with chronic kidney disease.
    • At a dose of 1.5 mg/m2, patients experienced a statistically significant improvement in kidney function as measured by the improvement in estimated glomerular filtration rate (eGFR) versus placebo (p=0.045). The improvement compared to placebo was maintained five weeks following the completion of dosing but the results were not statistically significant (p=0.07).
    • Also, no statistically significant improvement in eGFR was observed in the 30 mg/m2 dose group. The lack of consistent response may have been due to off-target drug effects considering the high dose.
    • In a subset of patients with diabetes, the 1.5 mg/m2 dose showed the strongest results compared to placebo (p=0.029).
    • Previously: La Jolla Pharma +22.4% AH. Wedbush starts at Outperform.
    • Previously: La Jolla Pharma +22.8% AH on positive trial results
    | Nov. 13, 2014, 4:10 PM
  • Nov. 13, 2014, 12:48 PM
    | Nov. 13, 2014, 12:48 PM | 14 Comments
  • Nov. 12, 2014, 6:00 PM
    • Along with its Q3 report, La Jolla Pharma (NASDAQ:LJPC) has announced the results of a Phase 2 study for its GCS-100 kidney disease drug.
    • La Jolla: "This multicenter, randomized, blinded, placebo-controlled, Phase 2 study in 121 advanced CKD patients met its primary efficacy endpoint of a statistically significant improvement in kidney function. Specifically, GCS-100, at a dose of 1.5 mg/m2, led to a statistically significant (p=0.045) improvement in estimated glomerular filtration rate (eGFR) versus placebo after 8 weeks of dosing."
    • The company adds GCS-100 was well-tolerated, with "no serious adverse effects."
    • Q3 results, PR
    | Nov. 12, 2014, 6:00 PM | 1 Comment
  • Jul. 15, 2014, 12:45 PM
    | Jul. 15, 2014, 12:45 PM
  • Jul. 15, 2014, 9:16 AM
    | Jul. 15, 2014, 9:16 AM | 7 Comments
  • Jul. 15, 2014, 9:07 AM
    • Shares of nano cap La Jolla Pharmaceuticals (NASDAQ:LJPC) are up 19% premarket on modest volume in response to its report of positive data for LJPC-1010 in a STAM model of non-alcoholic steatohepatitis (NASH). The experimental drug candidate showed a significant reduction in NAFLD score compared to a control vehicle.
    • The company plans to file an IND and initiate an Phase 1/2 clinical trial in 1H 2015.
    • The up move will undoubtedly attract short sellers considering the company's precarious cash situation and tiny market cap.
    | Jul. 15, 2014, 9:07 AM | 5 Comments
  • Jul. 11, 2014, 12:54 PM
    • Shares of thinly-traded La Jolla Pharmaceuticals (LJPC +22.5%) jump on a 5x surge in volume albeit on turnover of only ~500K shares. The company filed an S-3 on June 27 for a stock-and-warrant offering of $150M.
    • Wedbush raises its PT to $45 from $34, representing a ~4x rise from today's price. This is a clear signal that it is an underwriter on the issue.
    | Jul. 11, 2014, 12:54 PM | 1 Comment
Company Description
La Jolla Pharmaceutical Co. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics intended to significantly improve outcomes in patients with life-threatening diseases. It focuses on three product candidates: GCS-100, LJPC-501 and... More
Sector: Healthcare
Industry: Drug Related Products
Country: United States